[go: up one dir, main page]

WO2008043524A8 - Autoantigènes utilisés dans le diagnosic, le pronostic et le traitement améliorés de maladies neurologiques inflammatoires - Google Patents

Autoantigènes utilisés dans le diagnosic, le pronostic et le traitement améliorés de maladies neurologiques inflammatoires

Info

Publication number
WO2008043524A8
WO2008043524A8 PCT/EP2007/008776 EP2007008776W WO2008043524A8 WO 2008043524 A8 WO2008043524 A8 WO 2008043524A8 EP 2007008776 W EP2007008776 W EP 2007008776W WO 2008043524 A8 WO2008043524 A8 WO 2008043524A8
Authority
WO
WIPO (PCT)
Prior art keywords
autoantigens
treatment
prognosis
neurological diseases
improved diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/008776
Other languages
German (de)
English (en)
Other versions
WO2008043524A3 (fr
WO2008043524A2 (fr
Inventor
Ugur Sahin
Oezlem Tuereci
Alexander Zaigler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Original Assignee
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg Universitaet Mainz, Ganymed Pharmaceuticals GmbH filed Critical Johannes Gutenberg Universitaet Mainz
Priority to EP07818849A priority Critical patent/EP2076776A2/fr
Publication of WO2008043524A2 publication Critical patent/WO2008043524A2/fr
Publication of WO2008043524A8 publication Critical patent/WO2008043524A8/fr
Publication of WO2008043524A3 publication Critical patent/WO2008043524A3/fr
Priority to US12/420,627 priority patent/US8399210B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Selon l'invention des autoanticorps, dont l'apparence est caractéristique de maladies autoimmunes neurologiques, en particulier la sclérose en plaques, sont détectés et les autoantigènes correspondants sont identifiés. De plus, plusieurs autoantigènes peuvent être exprimés de manière spécifique dans le cerveau. L'identification desdits autoantigènes et des autoanticorps est utilisée dans le diagnostic et le traitement. Une expression spécifique au cerveau des autoantigènes souligne de plus le rôle important des antigènes et des anticorps dans l'origine et le développement de maladies autoimmunes neurologiques.
PCT/EP2007/008776 2006-10-11 2007-10-09 Autoantigènes utilisés dans le diagnosic, le pronostic et le traitement améliorés de maladies neurologiques inflammatoires Ceased WO2008043524A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07818849A EP2076776A2 (fr) 2006-10-11 2007-10-09 Autoantigènes utilisés dans le diagnosic, le pronostic et le traitement améliorés de maladies neurologiques inflammatoires
US12/420,627 US8399210B2 (en) 2006-10-11 2009-04-08 Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006048201A DE102006048201A1 (de) 2006-10-11 2006-10-11 Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
DE102006048201.8 2006-10-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/420,627 Continuation US8399210B2 (en) 2006-10-11 2009-04-08 Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases

Publications (3)

Publication Number Publication Date
WO2008043524A2 WO2008043524A2 (fr) 2008-04-17
WO2008043524A8 true WO2008043524A8 (fr) 2008-07-31
WO2008043524A3 WO2008043524A3 (fr) 2008-09-25

Family

ID=39078656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/008776 Ceased WO2008043524A2 (fr) 2006-10-11 2007-10-09 Autoantigènes utilisés dans le diagnosic, le pronostic et le traitement améliorés de maladies neurologiques inflammatoires

Country Status (4)

Country Link
US (1) US8399210B2 (fr)
EP (1) EP2076776A2 (fr)
DE (1) DE102006048201A1 (fr)
WO (1) WO2008043524A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2504024A2 (fr) * 2009-09-27 2012-10-03 Ruhr-Universität Bochum Méthode de thérapie et de diagnostic de morbus alzheimer
US9585380B2 (en) 2011-09-02 2017-03-07 Temple University—Of the Commonwealth System of Higher Education SSAT mRNA translation repression and activation
US12442818B2 (en) 2019-03-15 2025-10-14 Cz Biohub Sf, Llc Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer
CN114878828B (zh) * 2021-12-24 2023-03-10 天津天海新域生物科技有限公司 用于检测自身免疫性脑炎的抗体组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019919A1 (en) * 2000-09-14 2004-01-29 Peter Sonderegger Calcium binding proteins
US20030092089A1 (en) * 2001-11-14 2003-05-15 Moscarello Mario Anthony Method for diagnosing multiple sclerosis and an assay therefore
EP1597557A4 (fr) * 2002-10-11 2008-06-11 Univ California Methode permettant de diagnostiquer et de pronostiquer la sclerose en plaques
US20050142616A1 (en) * 2003-09-30 2005-06-30 Veneta Hanson Diagnostic test for neuropsychiatric systemic lupus erythematosus
EP1690870B1 (fr) * 2003-11-05 2012-03-28 Immuno-Biological Laboratories Co., Ltd. Peptide marqueur pour la maladie d'alzheimer
WO2006032126A1 (fr) * 2004-09-24 2006-03-30 Syn X Pharma, Inc. Diagnostic et traitement du prediabete de type 1 au moyen de proteines neuronales
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20100151483A1 (en) * 2006-07-13 2010-06-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways

Also Published As

Publication number Publication date
US20090252714A1 (en) 2009-10-08
WO2008043524A3 (fr) 2008-09-25
US8399210B2 (en) 2013-03-19
DE102006048201A1 (de) 2008-04-17
EP2076776A2 (fr) 2009-07-08
WO2008043524A2 (fr) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2010033279A3 (fr) <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
WO2008066691A3 (fr) Tes7, et anticorps se liant à celui-ci
WO2011012309A8 (fr) Anticorps muc1
EP4356927A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2009151717A3 (fr) Anticorps spécifiques du complexe bcr et procédés pour les utiliser
WO2007137984A3 (fr) Immunoglobulines
WO2009048538A3 (fr) Anticorps humanisé
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2011011426A3 (fr) Procédés d'évaluation d'un risque de maladie
TW200744634A (en) Methods of using antibodies against human IL-22
WO2009137832A3 (fr) Auto-anticorps dans la détection et le traitement du cancer
WO2006084075A3 (fr) Modulateurs adam-9
WO2006084078A3 (fr) Antigene jam-3 et anticorps se liant a celui-ci
WO2013173761A3 (fr) Protéines de liaison à l'antigène st2
WO2008048970A8 (fr) Anticorps synthétiques
EP4538295A3 (fr) Molécules de liaison à l'antigène et leurs procédés d'utilisation
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
WO2010073012A3 (fr) Anticorps
WO2009048539A3 (fr) Anticorps monoclonal
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2012009442A3 (fr) Anticorps monoclonal anti-addl et ses utilisations
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2015117088A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
MX2010001237A (es) Nuevos anticuerpos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818849

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007818849

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE